Reversal of Cognitive Defects and Synaptic Deficits with P21

Journal Context: Journal of Alzheimer's Disease / Europe PMC | Identifiers: DOI: 10.3233/JAD-161245 / PMID: 28655141

Principal Investigators: Baazaoui, A., & Iqbal, K. (Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities)

Methodology: Preclinical longitudinal evaluation utilizing triple-transgenic mice (3xTg-AD) displaying aggressive genetic predispositions for heavy beta-amyloid and tau tangles. Treatment was initiated early during the organism's "synaptic compensation phase" (3 months of age) and continued for 18 months, tracking shifts in dendritic spine density and evaluating reference memory performance using the Morris Water Maze.

Key Findings: Long-term administration of P21 completely rescued the cognitive architecture of the treated subjects. The neurotrophic compound successfully prevented the loss of dendritic spines and reversed spatial memory impairments. The study verified that providing targeted neurotrophic reinforcement before the heavy onset of pathology allows the brain to maintain functional synaptic compensation, effectively blocking the onset of dementia-like behaviour.